Concentrations of substance P and prostaglandin E2 in synovial fluid of normal and abnormal joints of horses

American Journal of Veterinary Research

Volumn 61, Issue 6, 2000, Pages 714-718

  Kirker Head, Carl A ^a   Chandna, V K ^b,d   Agarwal, R K ^a,e   Morris, Elisabeth A ^c   Tidwell, Amy ^a   O'Callaghan, Michael W ^a,f   Rand, William ^d   Kumar, M S A ^b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d Minuteman Way ^*  (United States)

^e NATIONAL EYE INSTITUTE   (United States)

^f GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUIDAE;

PROSTAGLANDIN E2; SUBSTANCE P;

ANIMAL; ANIMAL DISEASE; ARTHROPATHY; ARTICLE; BIOSYNTHESIS; CHEMISTRY; FEMALE; HORSE; HORSE DISEASE; MALE; METABOLISM; NONPARAMETRIC TEST; OSTEOARTHRITIS; PATHOLOGY; RADIOGRAPHY; RADIOIMMUNOASSAY; SYNOVIAL FLUID;

ANIMALS; DINOPROSTONE; FEMALE; HORSE DISEASES; HORSES; JOINT DISEASES; MALE; OSTEOARTHRITIS; RADIOIMMUNOASSAY; STATISTICS, NONPARAMETRIC; SUBSTANCE P; SYNOVIAL FLUID;

EID: 0034199826     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.714     Document Type: Article

References (42)

1. Todhunter PG, Kincaid SA, Todhunter RJ, et al. Immunohistochemical analysis of an equine model of synovitis-induced arthritis. Am J Vet Res 1996;57:1080-1093.
2. Dinarello CA, Cannon JG, Wolff SM, et al. Tumor necrosis factor (Cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp MeA 1986;163:1433-1450.
3. O'Gara A. Interleukins and immune system 1. Lancet 1989;1:943-947.
4. O'Gara A. Interleukins and immune system 2. Lancet 1989;1:1003-1005.
5. Tracey KJ, Vassara H, Cerarni A. Cachectin/tumor necrosis factor. Lancet 1989;1:1122-1126.
6. Westacott CI, Sharif M. Cytokines in osteoarthritis: mediators or markers of joint destruction? Semin Arthr Rheum 1996;25:254-272.
7. Moulton PJ. Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br J Biomed Sci 1996;53:317-324.
8. Levine JD, Clark R, Devor M, et al. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984;226:547-9.
9. Levine JD, Collier DH, Basbaum AI, et al. Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis. J Rheum 1985;12:406-411.
10. Levine JD, Goetzl EJ, Basbaum AI. Contribution of the nervous system to the pathophysiology of rheumatoid arthritis and other polyarthritides. Rheum Dis Clin North Am 1987;13:369-383.
11. Kimball ES, Persico FJ, Vaught JL. Substance P, neurokinin A and neurokinin B induced generation of IL-1-like activity in P 388 d1 cells. J Immunol 1988;141:3564-3569.
12. Kimball ES. Substance P, cytokines and arthritis. Ann NY Acad Sci 1990;594:293-308.
13. Menkes CJ, Renoux M, Laoussadi S, et al. Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. J Rheum 1993;20:714-717.
14. Marshall KW, Chiu B, Inman RD. Substance P and arthritis: analysis of plasma and synovial fluid levels. Arthr Rheum 1990;33 :87-90.
15. Derwin KA, Glover RA, Wojtys EM. Nociceptive role of substance P in the knee joint of a patient with congenital insensitivity to pain. J Pediatr Orthoped 1994;14:258-262.
16. Lembeck P, Holzer P. Substance P as neurogenic mediator of antidromic vasodilatation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch Pharmacol 1979;310:175-183.
17. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987;1:893-895.
18. Lam FY, Ferrell WR. Capsaicin suppresses substance P-induced joint inflammation in the rat. Neurosci Lett 1989;105: 155-158.
19. Caron JP, Bowker RM, Abhold RH, et al. Substance P in the synovial membrane and fluid of the equine middle carpal joint. Equine Vet J 1992;24:364-366.
20. Bowker RM, Abbold RH, Caron JP, et al. Neuropeptidergic innervation of equine synovial joints. Am J Vet Res 1993;54: 1831-1839.
21. Bowker RM, Sonea IM, Vex KB, et al. Substance P innervation of equine synovial membranes: joint differences and neural and nonneural receptor localizations. Neuro Sci Lett 1993;164:76-80.
22. Hardy J, Bertone AL, Weisbrode SE, et al. Cell trafficking, mediator release, and articular metabolism in acute inflammation of innervated or denervated isolated equine joints. Am J Vet Res 1998;59:88-100.
23. Henderson B, Higgs GA. Synthesis of arachidonate oxidation products by synovial joint tissues during the development of chronic erosive arthritis. Arthr Rheum 1987;30:1149-1156.
24. 2 in equine joint disease. Vlaams Diergeneeskd Tijdschr 1994;63:187-191.
25. Kumar AM, Becker HM, Thompson T, et al. Effect of early exposure to delta-9-THC on the levels of opioid peptides, GnRH and substance P in the adult rat brain. Brain Res 1990;525:78-83.
26. Kream RM, Schoenfeld TM, Mancuso R, et al. Precursor forms of substance P (SP) in nervous tissue: detection with antisera to SP, SP-gly, SP-gly-lys. Proc Natl Acad Sci U S A 1985;82: 4832-4836.
27. Kumar MSA, Solomon J, Patel V, et al. Early exposure to delta 9-THC influences neuroendocrine and reproductive functions in female rats. Neuroendocrinology 1986;44:260-264.
28. 2 in the synovial fluid of horses affected with arthropathy. Clin Vet 1980;544-549.
29. 2 values in horses. Am J Vet Res 1993;54:379-386.
30. Gibson KT, Hodge H, Whittem T. Inflammatory mediators in equine synovial fluid. Aust Vet J 1996;73:148-151.
31. Owens JG, Kamerling SG, Stanton SR, et al. Effects of pre-treatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses. Am J Vet Res 1996;57:866-874.
32. Gronblad M, Korkala O, Konttinen YT, et al. Immunoreactive neuropeptides in nerves in ligamentous tissue. Clin Orthop 1991;265:291-296.
33. Holmlund A, Ekblom A, Hansson P, et al. Concentrations of neuropeptides substance P neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid of the human temporomandibular joint. A correlation with symptoms, signs and arthroscopic findings. Int J Oral Maxillofac Surg 1991;20:228-231.
34. Pritchett JW. Substance P level in synovial fluid may predict pain relief after knee replacement surgery. J Bone Joint Surg Br 1997;79:114-116.
35. Arnalich F, de Miguel E, Perez-Ayala C, et al. Neuropeptides and interleukin 6 in human joint inflammation. Relationship between intraarticular substance P and interleukin-6 concentrations. Neurosd Lett 1994;170:251-254.
36. Hernanz A, De Miguel E, Romera N, et al. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheum 1993;32:31-35.
37. 2 levels in rabbit knee joints. Agents Actions 1991;34:46-48.
38. Fortier LA, Nixon AJ. Distributional changes in substance P nociceptive fiber patterns in naturally osteoarthritic articulations. J Rheum 1997;24:524-530.
39. Sipe JD. Arthritis and rheumatism. Semin Arthr Rheum 1995;25:75-86.
40. Ogonowski AA, May SW, Moore AB, et al. Antiinflammatory and analgesic activity of an inhibitor of neuropeptide amidation. J Pharmacol Exp Ther 1997;260:846-853
41. Lam FY, Ferrel WR. Neurogenic component of different models of acute inflammation in the rat knee joint. Annals Rheum Dis 1991;50:747-751.
42. Yaksh TL. Substance P release from knee joint afferent terminals: modulation by opioids. Brain Res 1988;458:319-324.